R. Connolly and V. Stearns, Current approaches for neoadjuvant chemotherapy in breast cancer, European Journal of Pharmacology, vol.717, issue.1-3, pp.58-66, 2013.
DOI : 10.1016/j.ejphar.2013.02.057

M. Kaufmann, G. Von-minckwitz, H. Bear, A. Buzdar, P. Mcgale et al., Recommendations From an International Expert Panel on the Use of Neoadjuvant (Primary) Systemic Treatment of Operable Breast Cancer: An Update, Journal of Clinical Oncology, vol.24, issue.12, pp.1927-1934, 2006.
DOI : 10.1200/JCO.2005.02.6187

P. Cortazar, L. Zhang, M. Untch, K. Mehta, J. Costantino et al., Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis, The Lancet, vol.384, issue.9938, pp.164-172, 2014.
DOI : 10.1016/S0140-6736(13)62422-8

J. Mieog, J. Van-der-hage, and C. Van-de-velde, Preoperative chemotherapy for women with operable breast cancer. The Cochrane database of systematic reviews, p.5002, 2007.

S. Hansen, D. Grabau, F. Sorensen, M. Bak, W. Vach et al., The prognostic value of angiogenesis by Chalkley counting in a confirmatory study design on 836 breast cancer patients. Clinical cancer research : an official journal of the American Association for, Cancer Research, vol.6, issue.1, pp.139-146, 2000.

N. Weidner, J. Folkman, F. Pozza, P. Bevilacqua, E. Allred et al., Tumor Angiogenesis: A New Significant and Independent Prognostic Indicator in Early-Stage Breast Carcinoma, JNCI Journal of the National Cancer Institute, vol.84, issue.24, pp.1875-1887, 1992.
DOI : 10.1093/jnci/84.24.1875

G. Gasparini, M. Toi, P. Verderio, G. Ranieri, S. Dante et al., Prognostic significance of p53, angiogenesis, and other conventional features in operable breast cancer: subanalysis in node-positive and node-negative patients., International Journal of Oncology, vol.12, issue.5, pp.1117-1125, 1998.
DOI : 10.3892/ijo.12.5.1117

A. Padhani and A. Khan, Diffusion-weighted (DW) and dynamic contrast-enhanced (DCE) magnetic resonance imaging (MRI) for monitoring anticancer therapy, Targeted Oncology, vol.9, issue.4, pp.39-52, 2010.
DOI : 10.1007/s11523-010-0135-8

P. Tofts, D. Wicks, G. Barker, P. Tofts, G. Brix et al., The MRI measurement of NMR and physiological parameters in tissue to study disease process Progress in clinical and biological research Estimating kinetic parameters from dynamic contrast-enhanced T(1)-weighted MRI of a diffusable tracer: standardized quantities and symbols, Journal of magnetic resonance imaging : JMRI, vol.363, issue.103, pp.313-325223, 1991.

H. Koo, N. Cho, I. Song, H. Kim, J. Chang et al., Correlation of perfusion parameters on dynamic contrast-enhanced MRI with prognostic factors and subtypes of breast cancers, Journal of Magnetic Resonance Imaging, vol.62, issue.Pt 1, pp.145-151, 2012.
DOI : 10.1002/jmri.23635

J. Kim, S. Kim, Y. Kim, B. Kang, Y. An et al., Enhancement parameters on dynamic contrast enhanced breast MRI: do they correlate with prognostic factors and subtypes of breast cancers?, Magnetic Resonance Imaging, vol.33, issue.1, pp.72-80, 2015.
DOI : 10.1016/j.mri.2014.08.034

Y. Yuan, X. Chen, S. Liu, and K. Shen, Accuracy of MRI in Prediction of Pathologic Complete Remission in Breast Cancer After Preoperative Therapy: A Meta-Analysis, American Journal of Roentgenology, vol.195, issue.1, pp.260-268, 2010.
DOI : 10.2214/AJR.09.3908

A. Padhani, C. Hayes, L. Assersohn, T. Powles, A. Makris et al., Prediction of Clinicopathologic Response of Breast Cancer to Primary Chemotherapy at Contrast-enhanced MR Imaging: Initial Clinical Results, Radiology, vol.239, issue.2, pp.361-374, 2006.
DOI : 10.1148/radiol.2392021099

S. Li, A. Makris, M. Beresford, N. Taylor, M. Ah-see et al., Use of Dynamic Contrast-enhanced MR Imaging to Predict Survival in Patients with Primary Breast Cancer Undergoing Neoadjuvant Chemotherapy, Radiology, vol.260, issue.1, pp.68-78, 2011.
DOI : 10.1148/radiol.11102493

R. Abramson, X. Li, T. Hoyt, P. Su, L. Arlinghaus et al., Early assessment of breast cancer response to neoadjuvant chemotherapy by semi-quantitative analysis of high-temporal resolution DCE-MRI: preliminary results Role of dynamic contrast enhanced MRI in monitoring early response of locally advanced breast cancer to neoadjuvant chemotherapy. Breast cancer research and treatment Prognostic value of pre-treatment DCE-MRI parameters in predicting disease free and overall survival for breast cancer patients undergoing neoadjuvant chemotherapy Pre-treatment differences and early response monitoring of neoadjuvant chemotherapy in breast cancer patients using magnetic resonance imaging: a systematic review, Magnetic resonance imaging. European journal of radiology. European radiology. Holmen MM, vol.31, issue.2212, pp.1457-1464498, 2005.

X. Li, L. Cheng, M. Liu, Y. Zhang, J. Wang et al., Dynamic enhanced MRI predicts chemosensitivity in breast cancer patients Neoadjuvant chemotherapy for breast cancer: correlation between the baseline MR imaging findings and responses to therapy. European radiology Measurement of the blood-brain barrier permeability and leakage space using dynamic MR imaging. 1. Fundamental concepts. Magnetic resonance in medicine Breast cancer subtypes and the risk of local and regional relapse Molecular portraits of human breast tumours Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer Pathologic response to induction chemotherapy in locally advanced carcinoma of the breast: a determinant of outcome, 29. DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach, pp.425-431270, 1988.

S. Li, A. Padhani, N. Taylor, M. Beresford, M. Ah-see et al., Vascular characterisation of triple negative breast carcinomas using dynamic MRI, European Radiology, vol.257, issue.1, pp.1364-1373, 2011.
DOI : 10.1007/s00330-011-2061-2

L. Carey, E. Dees, L. Sawyer, L. Gatti, D. Moore et al., The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes Clinical cancer research : an official journal of the American Association for Cancer Research Strategies for subtypes--dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer A new histological grading system to assess response of breast cancers to primary chemotherapy: prognostic significance and survival al. Clinical and pathological response to primary chemotherapy in operable breast cancer, Annals of oncology : official journal of the European Society for Medical Oncology / ESMO. Breast European journal of cancer, vol.13, issue.35, pp.2329-23341736, 1990.

K. Kranenbarg and W. , Accuracy of MRI for treatment response assessment after taxane-and anthracycline-based neoadjuvant chemotherapy in HER2-negative breast cancer Lenograstim prevents morbidity from intensive induction chemotherapy in the treatment of inflammatory breast cancer al. A new prognostic classification after primary chemotherapy for breast cancer: residual disease in breast and nodes (RDBN) Cancer journal, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, vol.40, issue.142, pp.1216-12211564, 1995.

Y. Zhao, X. Dong, R. Li, X. Ma, J. Song et al., Evaluation of the pathological response and prognosis following neoadjuvant chemotherapy in molecular subtypes of breast cancer. OncoTargets and therapy Pathologic response and long-term follow-up in breast cancer patients treated with neoadjuvant chemotherapy: a comparison between classifications and their practical application Archives of pathology & laboratory medicine, pp.1511-15211074, 2013.

S. Mombelli, F. Kwiatkowski, C. Abrial, Q. Wang-lopez, P. De-boissieu et al., Prognostic Factors in Operable Breast Cancer Treated with Neoadjuvant Chemotherapy: Towards a Quantification of Residual Disease, Oncology, vol.88, issue.5, pp.261-272, 2015.
DOI : 10.1159/000368557

N. Cho, S. Im, I. Park, K. Lee, M. Li et al., Breast cancer: early prediction of response to neoadjuvant chemotherapy using parametric response maps for MR imaging Penault-Llorca F, Vincent-Salomon A. [Roles of the pathologist in neoadjuvant chemotherapy: evaluation of response, prognostic and predictive factors], Radiology. Annales de pathologie, vol.272, issue.236, pp.385-396555, 2003.

C. Abrial, F. Bouchet-mishellany, I. Raoelfils, A. Cayre, H. Cure et al., Place of anatomopathology in evaluation of response to neoadjuvant chemotherapy. Prognostic and predictive markers: example of breast cancer], Bulletin du cancer, vol.93, issue.7, pp.663-668, 2006.

N. Houssami, P. Macaskill, G. Von-minckwitz, M. Marinovich, and E. Mamounas, Meta-analysis of the association of breast cancer subtype and pathologic complete response to neoadjuvant chemotherapy, European Journal of Cancer, vol.48, issue.18, pp.3342-3354, 1990.
DOI : 10.1016/j.ejca.2012.05.023

Y. Kim, J. Lee, J. Baek, G. Sung, D. Lee et al., The clinical significance of standardized uptake value in breast cancer measured using 18F-fluorodeoxyglucose positron emission tomography/computed tomography. Nuclear medicine communications, pp.790-794, 2015.

A. Padhani, N. Taylor, M. Ah-see, J. Stirling, and A. Makris, Accuracy of perfusion MRI with high spatial but low temporal resolution to assess invasive breast cancer response to neoadjuvant chemotherapy: a retrospective study Interand intraobserver variability in the evaluation of dynamic breast cancer MRI, BMC cancer. Journal of magnetic resonance imaging : JMRI, vol.11, issue.246, pp.1316-1325, 2006.

I. De-perfusion and T. , TDM avant chimiothérapie néoadjuvante pour prédire la réponse histologique des cancers du sein Résumé : But : Etablir un pronostic de réponse avant chimiothérapie néoadjuvante (CNA)

M. Matériel, Etude rétrospective monocentrique de patientes ayant bénéficié avant CNA d'une IRM perfusionnelle et d'un PET-TDM avec cartographie microcirculatoire (K trans , kep, ve) et mesure du SUVmax. Les paramètres d'imagerie ont été comparés avec la réponse tumorale et ganglionnaire après chirurgie selon Sataloff, les facteurs histo-pronostiques des tumeurs (grade SBR, récepteurs hormonaux, pp.2-53

D. Baseline and P. , as a predictor of pathologic response in patients treated with neodjuvant chemotherapy (NAC) for locally advanced breast cancer Abstract